EUVIMEDEUVIMED entdecken
Crossref

Antimicrobial resistance in Neisseria gonorrhoeae in England and Wales; findings from the gonococcal resistance to antimicrobials surveillance programme (GRASP 2024)

Suzy Sun, Prarthana Narayanan iD, Melissa Jansen van Rensburg, Anna Vickers, Sandhya Vivekanand, Penelope Cliff, Rachel Pitt-Kendall, Sandra David, Ella Breese, Emma Callan, Michelle J Cole, Hamish Mohammed und 4 weitere

International Journal of STD & AIDS · 2026-07 · 37 (8) · 870-875

DOI: 10.1177/09564624261443879 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of STD & AIDS, online erschienen am 16.04.2026. Verfasst von Suzy Sun und 15 weiteren Autor:innen. Beteiligte Einrichtung: Blood Safety, Hepatitis, STI & HIV Division, UK Health Security Agency, London, UK. Hauptthemen laut MEDLINE: Neisseria gonorrhoeae, Gonorrhea, Anti-Bacterial Agents, Drug Resistance, Bacterial. Die Arbeit nennt 12 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Gonococcal resistance in England and Wales has been monitored since 2000 by the Gonococcal Resistance to Antimicrobials Surveillance Programme (GRASP). Here we present the findings from the 2024 sentinel data and describe the recent trends in gonococcal susceptibility.

Methods

Consecutive N. gonorrhoeae isolates from 22 clinics, collected during August-September 2024, were sent by participating laboratories to the UK Health Security Agency (UKHSA) STI Reference Laboratory (STIRL) for antimicrobial susceptibility testing. Data are linked to the national STI surveillance system and further supplemented by participating sexual health clinics.

Results

N. gonorrhoeae remains highly susceptible to the first-line treatment, ceftriaxone, with just 1.7% of isolates (25/1,512) having reduced susceptibility (MIC >0.03 mg/L); 3.1% of isolates were resistant to the oral alternative treatment, cefixime (MIC >0.125 mg/L). Reduced susceptibility to azithromycin (ECOFF >1 mg/L) was 13.6%; however, most isolates (87.9%) had an azithromycin MIC of 2 mg/L, immediately above the ECOFF. Most isolates (90.6%) were resistant to tetracycline (MIC >0.5 mg/L). A quarter of isolates (25.9%) were resistant to penicillin (MIC >1 mg/L), nearly double that the proportion in the previous year. Ciprofloxacin susceptibility was predicted from genomic data; resistance decreased from 58.7 in 2023 to 46.4%. Prescribing data demonstrated excellent adherence to the UK guideline for managing infection with N. gonorrhoeae , with 97.0% of individuals receiving the recommended first-line of ceftriaxone 1g intramuscular monotherapy in 2024.

Conclusions

Cefixime resistance and azithromycin reduced susceptibility levels are concerning and may have implications for their use as second-line treatments in the future. Most isolates were resistant to tetracycline, supporting limited expectations for doxyPEP in reducing N. gonorrhoeae incidence.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neisseria gonorrhoeaeGonorrheaAnti-Bacterial AgentsDrug Resistance, BacterialHumansWalesEnglandMicrobial Sensitivity TestsAzithromycinThird Generation CephalosporinsCeftriaxoneCefiximeFemaleMaleSentinel SurveillanceSecond Generation CephalosporinsTetracyclineDrug Resistance, Multiple, BacterialCiprofloxacin

Stichwörter der Autor:innen

GonorrhoeaNeisseria gonorrhoeaeantimicrobial resistancesurveillance

Substanzen

Anti-Bacterial AgentsAzithromycinThird Generation CephalosporinsCeftriaxoneCefiximeSecond Generation CephalosporinsTetracyclineCiprofloxacin

Autor:innen und Institutionen

  • Blood Safety, Hepatitis, STI & HIV Division, UK Health Security Agency, London, UK.
  • Specialised Microbiology and Laboratories, UK Health Security Agency, London, UK.
  • Population Health Sciences, The National Institute for Health and Care Research Health Protection Research Unit in Blood Borne and Sexually Transmitted Infections at University College London in Partnership with the UK…
  • Institute for Global Health, University College, London, UK.

ORCID-Profile: Prarthana Narayanan, Helen Fifer

Zitieren

APA

Sun, S., Narayanan, P., Jansen van Rensburg, M., Vickers, A., Vivekanand, S., Cliff, P., Pitt-Kendall, R., David, S., Breese, E., Callan, E., Cole, M. J., Mohammed, H., Sinka, K., Alexander, S., Fifer, H., & GRASP Collaborators (2026). Antimicrobial resistance in Neisseria gonorrhoeae in England and Wales; findings from the gonococcal resistance to antimicrobials surveillance programme (GRASP 2024). International Journal of STD & AIDS, 37(8), 870-875. https://doi.org/10.1177/09564624261443879

Vancouver

Sun S, Narayanan P, Jansen van Rensburg M, Vickers A, Vivekanand S, Cliff P, et al. Antimicrobial resistance in Neisseria gonorrhoeae in England and Wales; findings from the gonococcal resistance to antimicrobials surveillance programme (GRASP 2024). International Journal of STD & AIDS. 2026;37(8):870-875. doi:10.1177/09564624261443879

BibTeX
@article{Sun2026,
  author = {Sun, Suzy and Narayanan, Prarthana and Jansen van Rensburg, Melissa and Vickers, Anna and Vivekanand, Sandhya and Cliff, Penelope and Pitt-Kendall, Rachel and David, Sandra and Breese, Ella and Callan, Emma and Cole, Michelle J and Mohammed, Hamish and Sinka, Katy and Alexander, Sarah and Fifer, Helen and GRASP Collaborators, GRASP Collaborators},
  title = {Antimicrobial resistance in Neisseria gonorrhoeae in England and Wales; findings from the gonococcal resistance to antimicrobials surveillance programme (GRASP 2024)},
  journal = {International Journal of STD & AIDS},
  year = {2026},
  volume = {37},
  number = {8},
  pages = {870--875},
  doi = {10.1177/09564624261443879}
}
Kostenlos starten →